Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis
The goal of this interventional double blind, randomized placebo controlled trial was to assess the change in functional mobility, quality of life and cognition for subjects who receive physical therapy and take dalfampridine vs…
- Trial name
- NCT05859802
- Testing
- Dalfampridine Pill
- Volunteers
- 35 people
- Sponsor
- D'Youville College
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
Part 1: The primary objective is to evaluate the efficacy of natalizumab extended interval dosing (EID) (every 6 weeks [Q6W]) in participants who have previously been treated with natalizumab standard interval dosing (SID) (every…
- Trial name
- NCT03689972
- Testing
- Natalizumab
- Where
- 107 sites in United States, Australia and 9 more
- Volunteers
- 585 people
- Sponsor
- Biogen
Multiple Sclerosis
Armergometry to Improve Mobility in MS
Chronic progressive multiple sclerosis patients will be randomised to home-based arm ergometry training for 12 weeks or a waitlist control group which will have access to the treatment after 12 weeks when primary endpoint…
- Trial name
- AMBOS (NCT03147105)
- Testing
- arm ergometry
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis
Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS
The purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with Multiple Sclerosis.
- Trial name
- STEM (NCT03983681)
- Testing
- Strategy-Based Training to Enhance Memory (STEM)
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Kessler Foundation
Relapsing Remitting Multiple Sclerosis
Flupirtine as Oral Treatment in Multiple Sclerosis
Flupirtine, a non-opioid analgesic drug, that has been shown to have additional neuroprotective functions, is given twice daily as an oral medication in patients with relapsing remitting multiple sclerosis over a period of 12…
- Trial name
- FLORIMS (NCT00623415)
- Testing
- Flupirtine
- Where
- 4 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Injury Brain, Eye Abnormalities
Reading Problems Associated With Central Nervous System (CNS) Pathologies.
This project aims to analyse eye movements, their alterations and influence in reading performance in patients with acquired CNS diseases and compare them with people of the same age, without neurological or ocular pathology and…
- Conditions
- Injury Brain, Eye Abnormalities, Multiple Sclerosis, Parkinson Disease
- Trial name
- NCT04937725
- Testing
- eye tracking
- Where
- Spain
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Relapsing-Remitting Multiple Sclerosis
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- GLOW (NCT01578785)
- Testing
- Glatiramer Acetate
- Where
- 169 sites in United States, Albania and 17 more
- Volunteers
- 178 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Chronic Pain
Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders
Participants with neurological disorders will be recruited to complete sessions of virtual reality (VR) immersion. VR has been shown to have therapeutic benefit in certain patient populations and requires further clinical study…
- Conditions
- Multiple Sclerosis, Chronic Pain, Neurological Disorder
- Trial name
- NCT03606668
- Testing
- HTC Vive Virtual Reality (VR) system
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Krabbe Disease
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.
- Trial name
- NCT06308718
- Testing
- FBX-101
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Forge Biologics, Inc
Multiple Sclerosis
Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis
The investigators principal hypothesis is that INO and optic neuritis are objective, quantitative, and reproducible models for corroborating the hypothesis that changes in core body temperature are associated with the reversible…
- Trial name
- NCT00854750
- Testing
- ACTHAR
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Elliot Frohman
Multiple Sclerosis
Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last Year
the aim of the study was to assess the occurrence of sensory integration disorders in people with SI depending on the stage of the disease and relapses in the last year;analysis of sensory integration disorders in patients with…
- Trial name
- NCT05449574
- Testing
- Scale for the Assessment of Sensory Integration in Adults
- Where
- Poland
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Pomeranian Medical University Szczecin
Multiple Sclerosis, Emotional Disturbances
A Social Emotion Regulation Intervention in MS
The current project will examine effectiveness of an intervention based on the concept of the social regulation of emotion. The intervention is designed to improve well-being in individuals with MS by leveraging participants'…
- Trial name
- NCT03951974
- Testing
- Social Emotion Regulation Strategy Development, Control
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Kessler Foundation
Relapsing-Remitting Multiple Sclerosis
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis
The aim of this project is to assess properly the clinical efficacy of TolDec therapy by imaging, clinical and surrogate end-points related with the activity of the disease.
- Trial name
- TolDecCOMBINEM (NCT04530318)
- Testing
- Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
- Where
- 5 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Judit Pich
Neurologic Disorder, Parkinson Disease
High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners
Individuals with and without neurologic diagnoses greatly benefit from participation in regular exercise but the majority are physically inactive.
- Conditions
- Neurologic Disorder, Parkinson Disease, Spinal Cord Injuries, Spina Bifida
- Trial name
- SHIFT-AR (NCT05951985)
- Testing
- HIFT
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Arkansas Colleges of Health Education
Relapsing-remitting Multiple Sclerosis, RRMS
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with…
- Trial name
- NCT01051817
- Testing
- AIN457
- Where
- 16 sites in Czechia, Russia and 1 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing, Remitting
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects.
- Trial name
- SEPTIME (NCT01201343)
- Testing
- Interferon beta-1a
- Volunteers
- 79 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension…
- Trial name
- NCT00239655
- Testing
- MK0812
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Muscle Spasticity Due to Multiple Sclerosis
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis
- Trial name
- NCT01649050
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluation of a Self-management Programme to Prevent Falls in People With Multiple Sclerosis
The goal of this randomized controlled trial is to evaluate the effects of a digital group based self-management fall prevention intervention, "Fewer Falls", in people with multiple sclerosis (PwMS).
- Trial name
- Fewer Falls (NCT05789225)
- Testing
- Fall prevention programme, Leaflet
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Karolinska Institutet
Multiple Sclerosis
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at…
- Trial name
- NCT01535664
- Testing
- Withdrawal of dalfampridine-ER 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Acorda Therapeutics